J&J/Janssen gain 1st US approval in MDR-TB with Sirturo
This article was originally published in Scrip
Executive Summary
The US FDA and Janssen, a subsidiary of Johnson & Johnson, waited until the last day of 2012 to reveal regulators had granted an accelerated approval three days earlier to Sirturo (bedaquiline) as the first drug in the US to treat pulmonary multi-drug resistant tuberculosis (MDR-TB).
You may also be interested in...
Pharma, Non-Profits Ally To Advance TB Drug Combinations
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.